San Francisco Sentry Investment Group (ca) Lowers stake in Gilead Sciences (GILD) – Market Digest

Gilead Sciences (GILD) : San Francisco Sentry Investment Group (ca) reduced its stake in Gilead Sciences by 0.4% during the most recent quarter end. The investment management company now holds a total of 9,328 shares of Gilead Sciences which is valued at $676,373 after selling 37 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Nov 1, 2016.Gilead Sciences makes up approximately 0.42% of San Francisco Sentry Investment Group (ca)’s portfolio.

Other Hedge Funds, Including , Valueworks reduced its stake in GILD by selling 752 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 72,811 shares of GILD which is valued at $5,279,526. Gilead Sciences makes up approx 5.06% of Valueworks’s portfolio.Edmonds Duncan Registered Investment Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 6,036 shares of Gilead Sciences which is valued at $444,431. Gilead Sciences makes up approx 0.27% of Edmonds Duncan Registered Investment Advisors’s portfolio. Equitec Proprietary Markets sold out all of its stake in GILD during the most recent quarter. The investment firm sold 1,500 shares of GILD which is valued $111,225.Nationwide Fund Advisors reduced its stake in GILD by selling 190,492 shares or 12.08% in the most recent quarter. The Hedge Fund company now holds 1,386,290 shares of GILD which is valued at $101,670,509. Gilead Sciences makes up approx 0.43% of Nationwide Fund Advisors’s portfolio.Rothschild Investment Corp Il boosted its stake in GILD in the latest quarter, The investment management firm added 7,385 additional shares and now holds a total of 37,189 shares of Gilead Sciences which is valued at $2,701,409. Gilead Sciences makes up approx 0.34% of Rothschild Investment Corp Il’s portfolio.

Gilead Sciences closed down -1.56 points or -2.11% at $72.51 with 1,46,19,961 shares getting traded on Wednesday. Post opening the session at $74, the shares hit an intraday low of $72.45 and an intraday high of $74.35 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Gilead Sciences reported $2.75 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Nov 1, 2016. Analyst had a consensus of $2.84. The company had revenue of $7500.00 million for the quarter, compared to analysts expectations of $7440.39 million. The company’s revenue was down -9.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.22 EPS.

Investors should note that on Nov 1, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Dec 13, 2016 as the ex-dividend date and fixed the record date on Dec 15, 2016. The payable date has been fixed on Dec 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Nov 2, 2016 to “Outperform” and Lowered the Price Target to $ 90 from a previous price target of $95 .Company shares were Reiterated by Jefferies on Oct 25, 2016 to “Buy”, Firm has raised the Price Target to $ 95 from a previous price target of $93 .Shares were Reiterated by RBC Capital Mkts on Oct 3, 2016 to “Outperform” and Lowered the Price Target to $ 95 from a previous price target of $105 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

San Francisco Sentry Investment Group (ca) Lowers stake in Gilead Sciences (GILD) – Market Digest

Leave a Reply

Your email address will not be published.